Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 9/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17222274 | 1.00 | HDAC4 (0.50) | HDAC4AKR1C1ELOVL1OPRL1HCAR2 | |
| SCHEMBL301133 | 0.83 | HDAC4 (0.59) | HDAC4AKR1C1ELOVL1OPRL1HCAR2 | |
| SCHEMBL31125559 | 0.83 | HDAC4 (0.59) | HDAC4AKR1C1ELOVL1OPRL1HCAR2 | |
| SCHEMBL30501854 | 0.81 | HDAC4 (0.62) | HDAC4AKR1C1ELOVL1OPRL1 | |
| SCHEMBL3184587 | 0.81 | HDAC4 (0.67) | HDAC4AKR1C1ELOVL1 | |
| SCHEMBL5637311 | 0.81 | HDAC4 (0.62) | HDAC4AKR1C1ELOVL1OPRL1 | |
| SCHEMBL31580968 | 0.81 | HDAC4 (0.67) | HDAC4AKR1C1ELOVL1 | |
| SCHEMBL17222255 | 0.81 | PSEN1 (0.42) | HDAC4ELOVL1 | |
| SCHEMBL17222252 | 0.81 | PSEN1 (0.42) | HDAC4ELOVL1 | |
| SCHEMBL27035072 | 0.81 | HDAC4 (0.49) | HDAC4AKR1C1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784671-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| WO-2019201283-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-9687459-B2 | Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs | PIERRE FABRE MEDICAMENT (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170065543-A1 | AMINOCYCLOBUTANE DERIVATIVES, METHOD FOR PREPARING SAME AND THE USE THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 2017-03-09 | — | — | US | disclosed |
| US-9469601-B2 | Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs | PIERRE FABRE MEDICAMENT (FR) | 2016-10-18 | — | — | US | disclosed |
| US-20150315132-A1 | AMINOCYCLOBUTANE DERIVATIVES, METHOD FOR PREPARING SAME AND THE USE THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315132-A1 | AMINOCYCLOBUTANE DERIVATIVES, METHOD FOR PREPARING SAME AND THE USE THEREOF AS DRUGS | GRIN1, GRIN3A, GRM1 | HDAC4 3435/4885AKR1C1 844/4885ELOVL1 3670/4885 |
| US-20170065543-A1 | AMINOCYCLOBUTANE DERIVATIVES, METHOD FOR PREPARING SAME AND THE USE THEREOF AS DRUGS | GRIN1, GRIN3A, GRM1 | HDAC4 3435/4885AKR1C1 844/4885ELOVL1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.